Phase 2 Study of Sapanisertib and Serabelisib PIKTOR With Paclitaxel for Advanced or Recurrent Endometrial Cancer
Led by Faeth Therapeutics · Updated on 2025-12-24
40
Participants Needed
18
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of the combination of sapanisertib and serabelisib PIKTOR with paclitaxel in women with advanced or recurrent endometrial cancer. This Phase 2, open-label, single-arm study focuses on participants who have previously undergone systemic therapies, including platinum-based chemotherapy and immune checkpoint inhibitors, but whose cancer has not responded or returned.
Participants will receive oral doses of sapanisertib and serabelisib together with intravenous paclitaxel. The study also includes a substudy that evaluates the combination of PIKTOR and paclitaxel with an insulin-suppressing diet. Treatment is administered under medical supervision at multiple centers.
During the study, participants will undergo regular assessments to monitor tumor response, disease progression, survival, and treatment safety over extended periodsup to two years for response assessment and up to five years for survival and progression measures. Researchers will track adverse events and overall treatment tolerability. The total study duration and follow-up will allow detailed evaluation of treatment effects and participant health.
CONDITIONS
Brief Title
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
Research Team
M
Medical Monitor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
PIKTOR (Sapanisertib + Serabelisib) with Paclitaxel
Physician’s Choice: Standard Single-Agent Chemotherapy
What is it?
An investigational oral combination therapy (Sapanisertib, an mTOR inhibitor, and Serabelisib, a PI3K-alpha inhibitor) added to standard paclitaxel infusion.
Standard single-agent chemotherapy (such as paclitaxel, doxorubicin, or carboplatin) chosen at the physician's discretion, as recommended for advanced/recurrent endometrial cancer after platinum-based chemotherapy and immune checkpoint inhibitor.
Role in trial
The only treatment arm studied in this trial; all enrolled participants receive PIKTOR plus paclitaxel.
Not studied in this trial, but represents the care typically given outside the study to similar patients.
Primary use
Being studied as a potential new treatment for advanced or recurrent endometrial cancer with a PI3K/AKT/mTOR pathway alteration after progression on standard therapies.
Used as guideline-recommended therapy for patients with advanced or recurrent disease progressing after platinum and immune checkpoint inhibitor.
How is it given or performed?
Oral PIKTOR drugs are taken in combination with intravenous paclitaxel, on a schedule as defined in the trial protocol.
Choice of intravenous or oral chemotherapy drugs; most commonly given as outpatient infusions at regular intervals, depending on the agent selected.
Evidence status
Efficacy and safety are under investigation in this trial; no published phase 2 or phase 3 results in endometrial cancer yet.
Well-established across multiple studies as standard-of-care therapy for this patient population.
Important limitations
Not yet proven effective for endometrial cancer; potential side effects and benefit-risk balance are still under investigation. Limited experience outside current trials, especially in the exact biomarker subgroup.
Response rates and durability are limited, especially after prior platinum and immunotherapy; side effects such as neuropathy and bone marrow suppression are common.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
FEMALE
Eligibility Criteria
You may qualify if you...
Histologically confirmed diagnosis of endometrioid endometrial carcinoma
Advanced or recurrent endometrial cancer not suitable for surgery or radiation to cure
Received 1 to 4 prior systemic therapies including platinum-based chemotherapy and a checkpoint inhibitor
PI3K/AKT/mTOR pathway gene alteration identified
At least 1 measurable target lesion per RECIST v1.1 criteria
ECOG performance status of 0 or 1 at screening
Non-pregnant, non-lactating females who are postmenopausal, surgically sterile, or agree to use effective contraception
You will not qualify if you...
Central nervous system metastases unless treated and off corticosteroids for at least 4 weeks before study
Active malignancy other than endometrial cancer within past 24 months except certain treated localized cancers
Conditions affecting absorption of study drugs such as gastric feeding tube or gastrointestinal issues
Clinically significant bleeding or hemoptysis
Significant cardiovascular impairment
Active uncontrolled infection requiring systemic antimicrobial therapy
Participation in another therapeutic clinical trial
Radiation therapy within 21 days prior to study treatment
Use of strong CYP3A4 inhibitors or inducers within 7 days before treatment
Requirement for proton pump inhibitors, chronic antacids, or histamine H2 blockers
Prolonged QTc interval over 480 ms
Poorly controlled diabetes or abnormal fasting glucose/triglycerides or insulin treatment
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Until disease progression or discontinuation
Participants receive sapanisertib and serabelisib orally and paclitaxel intravenously to treat advanced or recurrent endometrial cancer.
Regular visits for treatment administration and safety assessments as per protocol
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Safety and Dosimetry Study of 177Lu-RAD204 Targeting PD-L1 in Patients With Selected Metastatic Solid Tumors
Study of 177LuBetaBart Monoclonal Antibody for Safety and Early Effects in Adults With Advanced Solid Tumors
Evaluating 18F-T2 PETCT Imaging for Detecting Tumors with High CAIX Levels in Adults
Study of Using 3D-Printed Custom Devices for High-Dose Radiation Treatment in Gynaecological Cancer
Phase III Trial Comparing BNT323 Versus Chemotherapy for HER2-Positive Recurrent Endometrial Cancer
Study on Cervical and Endometrial Cancer in Women Aged 20 to 75
Open-Label Phase 1 Trial Evaluating Safety and Activity of HH160 Alone or With Other Cancer Treatments in Adults With Advanced or Metastatic Solid Tumors
Study of CTIM-76, a Claudin-6 Directed Bispecific Antibody, in Adults With Platinum-Resistant Ovarian Cancer and Advanced Solid Tumors
Phase 1 Open-label Study of LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, Given Intravenously in Advanced Solid Tumors to Determine Safety and Recommended Dose
Phase 1a1b Study of NRM-823 Alone and With Immune Checkpoint Inhibitor in Advanced or Metastatic Refractory Solid Tumors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Phase I dose escalation study of dual PI3K/mTOR inhibition by Sapanisertib and Serabelisib in combination with paclitaxel in patients with advanced solid tumors.
David C Starks, Luis Rojas-Espaillat, Tobias Meissner...